{
    "id": 3352,
    "name": "malignant fibrous histiocytoma of bone",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3352",
    "evidence": [
        {
            "id": 15300,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment of a patient with a malignant fibrous histiocytoma of bone, harboring an LMNA-NTRK1 fusion, resulted in a near complete response, as evidenced by an 18-month disease free follow-up (PMID: 30134855).",
            "molecularProfile": {
                "id": 12816,
                "profileName": "LMNA - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3352,
                "name": "malignant fibrous histiocytoma of bone",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13003,
                    "pubMedId": 30134855,
                    "title": "A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30134855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}